COVID supplement: Tetramer Research & Development

新冠肺炎补充剂：四聚体研究

• 批准号: 10678174
• 负责人: JOHN ALTMAN
• 金额: $ 20万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-21 至 2027-03-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678174
• 关键词: 2019-nCoV; Antigen Presentation Pathway; Area; Bar Codes; Binding Sites; Biotin; Communicable Diseases; Communities; Contracts; Core Facility; DNA; Disease; Immune; Immunology; MHC Class II Genes; Mediating; Mesocricetus auratus; Oligonucleotides; Performance; Production; Reagent; Research; Resources; Stains; Streptavidin; T cell response; T-Cell Activation; T-Lymphocyte; Technology; Time; United States National Institutes of Health; Variant; coronavirus disease; cost; fluorophore; neoplastic cell; novel; pathogenic microbe; research and development

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology (such as SARS-CoV-2) and a wide variety of infectious disease areas via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.

美国国立卫生研究院四聚体核心设施通过生产和销售I类、II类和CD1类试剂，为研究界提供了宝贵的资源，使基础免疫学(如SARS-CoV-2)和各种传染病领域的尖端研究成为可能。这些试剂正被应用于抗原处理和提呈、T细胞激活、T细胞对微生物病原体或肿瘤的反应以及T细胞介导的免疫介导性疾病的恶化或改善的研究。这份合同进行的研究和开发将提高现有四聚体试剂的质量、功能(例如灵敏度)和广度，并缩短生产时间。